ELLA (ulipristal acetate) by Teva is occur, ella postpones follicular rupture. First approved in 2010.
Drug data last refreshed 7h ago · AI intelligence enriched 1w ago
ELLA (ulipristal acetate) is an oral emergency contraceptive tablet approved in 2010 that works by inhibiting or delaying ovulation, with potential secondary effects on endometrial alterations affecting implantation. It is indicated for emergency contraception in women of reproductive age within a defined timeframe after unprotected intercourse. The drug represents a selective progesterone receptor modulator mechanism distinct from other emergency contraceptive options.
Product is at peak lifecycle with stable Medicare claims volume, indicating mature market penetration and established team structures focused on maintenance and optimization.
occur, ella postpones follicular rupture. The likely primary mechanism of action of ulipristal acetate for emergency contraception is therefore inhibition or delay of ovulation; however, alterations to the endometrium that may affect implantation may also contribute to efficacy.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1,1-difluoroethane (HFA-152a) and HFA-1,1,1,2-tetrafluoroethane (134a)
Echocardiographic Assessment of the Effect of Impella on Biventricular Function
A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Administered as Intramuscular Injection to Healthy Children 15 Months to 6 Years of Age
Mammogram Pretreatment With Ulipristal Acetate
INitiation and Titration of Guideline Directed Medical TheRApy in HearT Failure Cardiogenic Shock With ImpElla 5.5 for Cardiac Recovery
Worked on ELLA at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moTeva is hiring 1 role related to this product
LOE in ~4 years — strategic planning for patent cliff underway
ELLA careers are concentrated in small, specialized teams within R&D and Business Development, reflecting the product's mature lifecycle and focused commercial scope. Roles emphasize scientific expertise and strategic planning rather than broad commercial infrastructure typical of growth-stage products.
4 open roles linked to this drug